Table Of Contents
1. Introduction
1.1 Market Definition & Scope
1.2 Research Assumptions & Abbreviations
1.3 Research Methodology
2. Executive Summary
2.1 Market Snapshot
2.2 Market Absolute $ Opportunity Assessment & Y-o-Y Analysis, 2021–2032
2.3 Market Size & Forecast, By Segmentation, 2021–2032
2.3.1 Market Size By Technology
2.3.2 Market Size By Indication
2.3.3 Market Size By End-Use
2.4 Market Share & Bps Analysis By Region, 2024
2.5 Industry Growth Scenarios – Conservative, Likely & Optimistic
2.6 Industry CxO’s Perspective
3. Market Overview
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Key Market Trends
3.2 Industry PESTLE Analysis
3.3 Key Industry Forces (Porter’s) Impacting Market Growth
3.4 Industry Supply Chain Analysis
3.4.1 Raw Material Suppliers
3.4.2 Manufacturers
3.4.3 Distributors/Suppliers
3.4.4 Customers/End-Users
3.5 Industry Life Cycle Assessment
3.6 Parent Market Overview
3.7 Market Risk Assessment
4. Statistical Insights & Trends Reporting
4.1 Test Adoption & Utilization Metrics
4.1.1 Percentage of oncology patients receiving companion diagnostic testing before therapy
4.1.2 Adoption rate of companion diagnostics by hospital type (academic vs. community)
4.1.3 Annual growth in the number of patients tested per therapy type
4.2 Technology & Platform Statistics
4.2.1 Share of PCR-based vs. NGS-based companion diagnostic tests
4.2.2 Number of biomarker panels utilized per clinical application
4.2.3 Percentage of companion diagnostics integrated with electronic health record systems
4.3 Clinical & Regulatory Insights
4.3.1 Average time for regulatory approval of companion diagnostic tests by region
4.3.2 Percentage of tests co-developed with therapeutic drugs vs. independently developed
4.3.3 Number of ongoing clinical trials using companion diagnostic-guided therapies
4.4 Market Impact & ROI Metrics
4.4.1 Percentage reduction in treatment inefficacy due to diagnostic-guided therapies
4.4.2 Cost savings per patient from optimized drug prescription using companion diagnostics
4.4.3 Reimbursement coverage rate (%) for companion diagnostic tests by healthcare providers
5. Companion Diagnostics Market Segmental Analysis & Forecast, By Technology, 2021 – 2032, Value (USD Billion)
5.1 Introduction
5.2 Polymerase Chain Reaction
5.2.1 Key Trends
5.2.2 Market Size & Forecast, 2021 – 2032
5.3 Immunohistochemistry
5.4 In-situ Hybridization
5.5 Next Generation Gene Sequencing
5.6 Others
6. Companion Diagnostics Market Segmental Analysis & Forecast, By Indication, 2021 – 2032, Value (USD Billion)
6.1 Introduction
6.2 Cancer
6.2.1 Key Trends
6.2.2 Market Size & Forecast, 2021 – 2032
6.3 Neurological Diseases
6.4 Infectious Diseases
6.5 Others
7. Companion Diagnostics Market Segmental Analysis & Forecast, By End-User, 2021 – 2032, Value (USD Billion)
7.1 Introduction
7.2 Pharmaceutical & Biopharmaceutical Companies
7.2.1 Key Trends
7.2.2 Market Size & Forecast, 2021 – 2032
7.3 Reference Laboratories
7.4 Contract Research Organizations (CROs)
8. Companion Diagnostics Market Segmental Analysis & Forecast By Region, 2021 – 2025, Value (USD Billion)
8.1 Introduction
8.2 North America
8.2.1 Key Trends
8.2.2 Companion Diagnostics Market Size & Forecast, By Technology, 2021 – 2032
8.2.3 Companion Diagnostics Market Size & Forecast, By Indication, 2021 – 2032
8.2.4 Companion Diagnostics Market Size & Forecast, By End-Use, 2021 – 2032
8.2.5 Companion Diagnostics Market Size & Forecast, By Country, 2021 – 2032
8.2.5.1 USA
8.2.5.2 Canada
8.3 Europe
8.3.1 Key Trends
8.3.2 Companion Diagnostics Market Size & Forecast, By Technology, 2021 – 2032
8.3.3 Companion Diagnostics Market Size & Forecast, By Indication, 2021 – 2032
8.3.4 Companion Diagnostics Market Size & Forecast, By End-Use, 2021 – 2032
8.3.5 Companion Diagnostics Market Size & Forecast, By Country, 2021 – 2032
8.3.5.1 Germany
8.3.5.2 UK
8.3.5.3 France
8.3.5.4 Italy
8.3.5.5 Spain
8.3.5.6 Russia
8.3.5.7 Poland
8.3.5.8 Rest of Europe
8.4 Asia-Pacific
8.4.1 Key Trends
8.4.2 Companion Diagnostics Market Size & Forecast, By Technology, 2021 – 2032
8.4.3 Companion Diagnostics Market Size & Forecast, By Indication, 2021 – 2032
8.4.4 Companion Diagnostics Market Size & Forecast, By End-Use, 2021 – 2032
8.4.5 Companion Diagnostics Market Size & Forecast, By Country, 2021 – 2032
8.4.5.1 China
8.4.5.2 India
8.4.5.3 Japan
8.4.5.4 South Korea
8.4.5.5 Australia
8.4.5.6 ASEAN Countries
8.4.5.7 Rest of Asia-Pacific
8.5 Latin America
8.5.1 Key Trends
8.5.2 Companion Diagnostics Market Size & Forecast, By Technology, 2021 – 2032
8.5.3 Companion Diagnostics Market Size & Forecast, By Indication, 2021 – 2032
8.5.4 Companion Diagnostics Market Size & Forecast, By End-Use, 2021 – 2032
8.5.5 Companion Diagnostics Market Size & Forecast, By Country, 2021 – 2032
8.5.5.1 Brazil
8.5.5.2 Argentina
8.5.5.3 Mexico
8.5.5.4 Colombia
8.5.5.5 Rest of Latin America
8.6 Middle East & Africa
8.6.1 Key Trends
8.6.2 Companion Diagnostics Market Size & Forecast, By Technology, 2021 – 2032
8.6.3 Companion Diagnostics Market Size & Forecast, By Indication, 2021 – 2032
8.6.4 Companion Diagnostics Market Size & Forecast, By End-Use, 2021 – 2032
8.6.5 Companion Diagnostics Market Size & Forecast, By Country, 2021 – 2032
8.6.5.1 UAE
8.6.5.2 Saudi Arabia
8.6.5.3 Qatar
8.6.5.4 Egypt
8.6.5.5 South Africa
8.6.5.6 Rest of Middle East & Africa
9. Competitive Landscape
9.1 Key Players' Positioning
9.2 Competitive Developments
9.2.1 Key Strategies Adopted (%), By Key Players, 2024
9.2.2 Year-Wise Strategies & Development, 2021 – 2025
9.2.3 Number Of Strategies Adopted By Key Players, 2024
9.3 Market Share Analysis, 2024
9.4 Product/Service & Application Benchmarking
9.4.1 Product/Service Specifications & Features By Key Players
9.4.2 Product/Service Heatmap By Key Players
9.4.3 Application Heatmap By Key Players
9.5 Industry Start-Up & Innovation Landscape
9.6 Key Company Profiles
9.6.1 F. Hoffmann-La Roche Ltd.
9.6.1.1 Company Overview & Snapshot
9.6.1.2 Product/Service Portfolio
9.6.1.3 Key Company Financials
9.6.1.4 SWOT Analysis
9.6.2 Abbott Laboratories
9.6.3 QIAGEN N.V.
9.6.4 Thermo Fisher Scientific Inc.
9.6.5 Agilent Technologies, Inc.
9.6.6 Illumina, Inc.
9.6.7 Myriad Genetics, Inc.
9.6.8 BioMérieux SA
9.6.9 Guardant Health, Inc.
9.6.10 Foundation Medicine, Inc.
9.6.11 Siemens Healthineers AG
9.6.12 Danaher Corporation
9.6.13 Invitae Corporation
9.6.14 Almac Diagnostics
9.6.15 Leica Biosystems
9.6.16 Bio-Rad Laboratories, Inc.
9.6.17 MolecularMD
9.6.18 Quidel Corporation
9.6.19 ARUP Laboratories
9.6.20 Epic Sciences
10. Analyst Recommendations
10.1 SNS Insider Opportunity Map
10.2 Industry Low-Hanging Fruit Assessment
10.3 Market Entry & Growth Strategy
10.4 Analyst Viewpoint & Suggestions On Market Growth
11. Assumptions
12. Disclaimer
13. Appendix
13.1 List Of Tables
13.2 List Of Figures
